---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007864"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:40:34.768485+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics Q4 net loss $17.3M; FY2022 net loss $63.3M; cash $330M; DT-216 MAD data mid-2023

## Summary
- R&D expenses $14.3M (Q4) and $48.6M (FY2022); G&A $5.1M (Q4) and $19.0M (FY2022).
- Cash, equivalents and securities $330.4M as of Dec 31, 2022; expected runway through 2025.
- Phase 1 MAD trial of DT-216 for Friedreich Ataxia ongoing; initial data expected mid-2023, final by year-end.
- IND submission for DT-168 (FECD) planned H2 2023; DM1 program targeting IND in 2024.
- No revenue reported; net loss driven by R&D investment in clinical and preclinical pipeline.

## SEC filing metadata
- accession: 0000950170-23-007864
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017023007864/0000950170-23-007864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017023007864/dsgn-20230314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007864
- JSON: https://secwatch.observer/filing/0000950170-23-007864.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007864.txt

## Key facts
- Earnings Releases
  Design Therapeutics, Inc. reported three and twelve months ended December 31, 2022 results: net income Net loss was $17.3 million for the quarter ended December 31, 2022, and $63.3 million for the year ended December 31, 20.
  - Period: three and twelve months ended December 31, 2022
  - Net income: Net loss was $17.3 million for the quarter ended December 31, 2022, and $63.3 million for the year ended December 31, 20
  - Result: reported results
  source text: On March 14, 2023, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000095017023007864/0000950170-23-007864-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.